drug_type
RELEVANT_DRUG
intervention_type
Cellular gene therapy (autologous CAR T cells), intravenous administration
drug_description
Autologous CD79b-targeted chimeric antigen receptor (CAR) T-cell therapy. Patient T cells are genetically engineered to express a CAR recognizing CD79b (Igβ) on B cells; CAR engagement activates T cells to proliferate, release cytokines, and mediate perforin/granzyme-dependent cytotoxicity against CD79b-positive malignant B cells. Administered intravenously after leukapheresis for relapsed/refractory B-cell lymphomas.
nci_thesaurus_concept_id
C200460
nci_thesaurus_definition
A preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) B-cell antigen receptor complex-associated protein beta chain (CD79b; B-cell-specific glycoprotein B29), with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-CD79b CAR-T cells JV-213 target and bind to CD79b-expressing tumor cells, thereby inducing selective toxicity in CD79b-expressing tumor cells. CD79b, a critical receptor for successful B-cell development and part of the B-cell receptor (BCR) signaling complex, is widely expressed in certain subtypes of B-cell lymphomas.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells engineered to express an anti-CD79b chimeric antigen receptor bind CD79b on malignant B cells, triggering T-cell activation, proliferation, cytokine release, and perforin/granzyme-mediated cytotoxic killing of CD79b-positive cells.
drug_name
JV-213
nct_id_drug_ref
NCT05773040